See more : Jupiter Wagons Limited (JWL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Gyre Therapeutics, Inc. (GYRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gyre Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Salona Cotspin Limited (SALONACOT.BO) Income Statement Analysis – Financial Results
- Strait Innovation Internet Co., Ltd. (300300.SZ) Income Statement Analysis – Financial Results
- International Entertainment Corporation (1009.HK) Income Statement Analysis – Financial Results
- Serneke Group AB (publ) (SRNKE-B.ST) Income Statement Analysis – Financial Results
- Beaver Coal Company, Limited (BVERS) Income Statement Analysis – Financial Results
Gyre Therapeutics, Inc. (GYRE)
About Gyre Therapeutics, Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.45M | 794.00K | 7.34M | 20.95M | 0.00 | 6.00K | 1.02M | 399.00K | 1.75M | 275.00K | 3.63M | 57.86M | 97.64M | 85.71M | 25.06M | 20.09M | 11.58M | 27.54M | 1.18M | 3.74M | 2.46M | 2.29M | 1.70M |
| Cost of Revenue | 4.64M | 798.00K | 7.38M | 9.16M | 43.86M | 21.47M | 12.85M | 10.56M | 5.96M | 5.27M | 6.56M | 0.00 | 0.00 | 0.00 | 691.00K | 749.00K | 715.42K | 457.25K | 480.93K | 198.45K | 743.00K | 244.00K | 0.00 |
| Gross Profit | 108.81M | -4.00K | -42.00K | 11.79M | -43.86M | -21.47M | -11.83M | -10.16M | -4.21M | -4.99M | -2.93M | 57.86M | 97.64M | 85.71M | 24.37M | 19.34M | 10.86M | 27.08M | 698.98K | 3.54M | 1.72M | 2.04M | 1.70M |
| Gross Profit Ratio | 95.91% | -0.50% | -0.57% | 56.26% | 0.00% | -357,800.00% | -1,161.98% | -2,545.36% | -240.46% | -1,815.27% | -80.68% | 100.00% | 100.00% | 100.00% | 97.24% | 96.27% | 93.82% | 98.34% | 59.24% | 94.69% | 69.77% | 89.33% | 100.00% |
| Research & Development | 13.78M | 13.04M | 68.89M | 52.98M | 43.86M | 21.47M | 12.85M | 11.56M | 5.96M | 19.50M | 38.84M | 49.09M | 95.22M | 64.55M | 40.18M | 40.98M | 34.62M | 21.79M | 24.25M | 22.77M | 18.18M | 16.24M | 8.15M |
| General & Administrative | 14.66M | 17.37M | 18.96M | 16.18M | 13.42M | 12.35M | 9.99M | 9.26M | 9.59M | 10.17M | 12.01M | 13.19M | 12.17M | 8.05M | 8.17M | 6.50M | 8.01B | 5.70B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 61.16M | 54.24M | 44.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.00B | -5.69B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.82M | 17.37M | 18.96M | 16.18M | 13.42M | 12.35M | 9.99M | 9.26M | 9.59M | 10.17M | 12.01M | 13.19M | 12.17M | 8.05M | 8.17M | 6.50M | 8.01M | 5.70M | 6.39M | 5.16M | 3.60M | 4.14M | 2.30M |
| Other Expenses | 86.44M | -517.00K | -78.00K | 568.00K | -46.00K | 1.65M | 261.00K | 86.00K | 0.00 | 318.00K | 518.00K | 1.04M | 0.00 | 0.00 | 51.28M | 32.01M | 27.33B | 16.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.04M | 30.40M | 87.85M | 69.16M | 57.28M | 33.83M | 22.84M | 20.82M | 15.55M | 29.67M | 50.85M | 62.28M | 107.38M | 72.60M | 64.70M | 47.48M | 42.63M | 27.48M | 30.64M | 27.93M | 21.78M | 23.05M | 10.45M |
| Cost & Expenses | 180.68M | 31.20M | 95.23M | 78.32M | 57.28M | 33.83M | 22.84M | 20.82M | 15.55M | 29.67M | 50.85M | 62.28M | 107.38M | 72.60M | 65.39M | 48.23M | 43.35M | 27.94M | 31.12M | 28.13M | 22.52M | 23.29M | 10.45M |
| Interest Income | 0.00 | 537.00K | 39.00K | 1.13M | 2.10M | 3.77M | 261.00K | 3.47M | 518.00K | 585.00K | 784.00K | 1.07M | 1.22M | 1.46M | 1.05M | 2.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 717.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.48M | 23.00K | 53.00K | 86.00K | 132.00K | 153.00K | 217.00K | 251.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 1.11M | 1.13M | 290.00K | 138.00K | 146.00K | 149.00K | 173.00K | 389.00K | 470.00K | 351.00K | 547.00K | 2.21M | 2.48M | 2.00M | 1.84M | 1.80M | 907.16K | 820.92K | 803.19K | 766.34K | 0.00 | 0.00 | 0.00 |
| EBITDA | 20.33M | 10.33M | -87.60M | -57.37M | -57.28M | -33.82M | -21.82M | -16.95M | -12.81M | -29.71M | -47.22M | -8.14M | -9.75M | 13.12M | -40.33M | -28.14M | -30.86M | 417.23K | -29.14M | -23.13M | -20.06M | -21.00M | -8.75M |
| EBITDA Ratio | 17.92% | -6,568.39% | -1,193.84% | -273.87% | 0.00% | -563,700.00% | -2,143.61% | -4,246.87% | -732.23% | -10,349.09% | -1,301.07% | -1.21% | -9.98% | 15.30% | -160.90% | -140.12% | -266.63% | 1.52% | -2,469.47% | -631.90% | -816.27% | -918.77% | -513.86% |
| Operating Income | -67.23M | -8.61M | -87.89M | -57.37M | -57.28M | -33.82M | -21.82M | -20.42M | -13.80M | -29.71M | -47.22M | -8.14M | -9.75M | 13.12M | -40.33M | -28.14M | -31.77M | -403.69K | -29.94M | -24.39M | -20.06M | -21.00M | -8.75M |
| Operating Income Ratio | -59.26% | -1,084.51% | -1,197.79% | -273.87% | 0.00% | -563,700.00% | -2,143.61% | -5,117.29% | -788.69% | -10,805.09% | -1,301.07% | -14.06% | -9.98% | 15.30% | -160.90% | -140.12% | -274.46% | -1.47% | -2,537.54% | -652.51% | -816.27% | -918.77% | -513.86% |
| Total Other Income/Expenses | -9.74M | 209.00K | -39.00K | 1.13M | 2.10M | 3.77M | 261.00K | 3.47M | -960.00K | 575.00K | 518.00K | 1.04M | 1.22M | 1.31M | 833.00K | 2.48M | 3.70B | -1.24B | 949.39K | 368.04K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -76.97M | -7.89M | -87.93M | -56.24M | -55.18M | -30.06M | -21.56M | -16.95M | -14.76M | -29.14M | -46.70M | -7.10M | -8.53M | 14.43M | -39.49M | -25.66M | -28.07B | -1.24B | 0.00 | -24.40M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -67.84% | -994.21% | -1,198.32% | -268.48% | 0.00% | -500,916.67% | -2,117.98% | -4,246.87% | -843.54% | -10,596.00% | -1,286.80% | -12.27% | -8.74% | 16.83% | -157.58% | -127.76% | -242,510.84% | -4,489.05% | 0.00% | -652.63% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 8.52M | 348.00K | -39.00K | -699.00K | -2.29M | 3.77M | -173.00K | 3.08M | 518.00K | 3.48M | 7.00K | -101.00K | -2.48M | 3.53M | -88.00K | -4.28M | -3.70M | -2.50M | -949.39K | -368.04K | 19.40M | 21.07M | 7.30M |
| Net Income | -92.93M | 2.30M | -87.93M | -55.54M | -52.89M | -30.06M | -21.56M | -16.95M | -14.76M | -32.62M | -46.71M | -7.00M | -8.53M | 10.90M | -39.40M | -25.66M | -28.07M | 2.10M | -28.99M | -24.03M | -19.40M | -21.07M | -7.30M |
| Net Income Ratio | -81.92% | 289.92% | -1,198.32% | -265.14% | 0.00% | -500,916.67% | -2,117.98% | -4,246.87% | -843.54% | -11,862.91% | -1,286.99% | -12.09% | -8.74% | 12.72% | -157.23% | -127.76% | -242.51% | 7.61% | -2,457.08% | -642.67% | -789.06% | -921.78% | -428.77% |
| EPS | -1.41 | 0.04 | -2.87 | -2.90 | -4.41 | -2.68 | -6.30 | -21.76 | -49.99 | -101.40 | -145.78 | -21.95 | -28.31 | 39.90 | -161.39 | -109.24 | -149.47 | -9.45 | -11.62K | -11.51K | -18.68K | -8.10K | -2.81K |
| EPS Diluted | -1.41 | 0.03 | -2.87 | -2.90 | -4.41 | -2.68 | -6.30 | -21.76 | -49.99 | -101.40 | -145.78 | -21.95 | -28.31 | 37.80 | -161.39 | -109.24 | -149.47 | -9.45 | -11.62K | -11.51K | -18.68K | -8.10K | -2.81K |
| Weighted Avg Shares Out | 65.83M | 76.74M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 778.78K | 295.27K | 321.72K | 320.39K | 318.82K | 301.31K | 271.84K | 244.16K | 234.90K | 187.82K | 129.48K | 2.50K | 2.09K | 1.04K | 2.60K | 2.60K |
| Weighted Avg Shares Out (Dil) | 65.83M | 75.69M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 778.78K | 295.27K | 321.72K | 320.39K | 318.82K | 301.31K | 287.15K | 244.16K | 234.90K | 187.82K | 129.48K | 2.50K | 2.09K | 1.04K | 2.60K | 2.60K |
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Data readout from Phase 3 clinical trial in the People's Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver...
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company's Board of...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
Is It Time to Buy the Nasdaq's 5 Worst-Performing Stocks in February 2024?
Sigma Lithium, despite its vast reserves, faces challenges as lithium prices plummet, making its stock's steep drop a cautionary tale. Hut 8 and Cipher Mining may be promising bets on a Bitcoin turnaround in the long run, but they may...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
Source: https://incomestatements.info
Category: Stock Reports